Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Status Completed

Clinical Trial Summary

Cancer genetic counseling (CGC) has been found to have "substantial" benefits for individuals with breast cancer and their family members; it has been deemed by multiple organizations as "standard of care" for women with breast cancer and their relatives. Unfortunately, there is a disparity in access to CGC, especially among women who live in rural and underserved areas. In North Carolina, only two cancer genetic counselors practice in rural clinics - each only for a few days per month. Therefore, in an effort to make CGC more widely available in a timely manner, we propose to test provision of counseling through telemedicine (TM), in which a patient and health care provider communicate with each other using videoconferencing. In 4 rural oncology clinics, we will implement low-cost TM and compare satisfaction and cost-effectiveness between groups of women designated to have their CGC session by TM or FTF. We'll use a validated measure to assess satisfaction by a phone survey one week after the CGC appointment; cost-effectiveness will be measured at project's end by calculating length of wait time for appointment and costs of equipment, labor, and mileage. Study hypothesis: TM is as satisfactory as FTF counseling and is a more cost-effective way to provide this beneficial service.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

Hereditary Breast and Ovarian Cancer Syndrome
Lynch Syndrome
Ovarian Neoplasms
Syndrome

Clinical Trial Details

NCT number	NCT00609505
Study type	Interventional
Source	Duke University
Contact
Status	Completed
Phase	N/A
Start date	August 2008
Completion date	April 2011

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00217737` - Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	Phase 3
Completed	`NCT00905710` - Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome	N/A
Active, not recruiting	`NCT02194387` - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members	N/A
Recruiting	`NCT04909671` - Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.	N/A
Recruiting	`NCT04379999` - Atorvastatin ± Aspirin in Lynch Syndrome Syndrome	Early Phase 1
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed	`NCT01845753` - Molecular Screening for Lynch Syndrome in Denmark
Completed	`NCT01216930` - Molecular Screening for Lynch Syndrome in Southern Denmark	N/A
Not yet recruiting	`NCT05963191` - CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome	N/A
Active, not recruiting	`NCT02912559` - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	Phase 3
Recruiting	`NCT04978350` - Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study	N/A
Active, not recruiting	`NCT03832985` - Pediatric Reporting of Adult-Onset Genomic Results	Early Phase 1
Withdrawn	`NCT04778566` - Evaluating the Cologuard Test for Use in Lynch Syndrome
Completed	`NCT02570516` - NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome	N/A
Completed	`NCT01823471` - I-Scan For Colon Polyp Detection In HNPCC	N/A
Recruiting	`NCT02813824` - Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome	Phase 3
Recruiting	`NCT05078866` - Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients	Phase 1/Phase 2
Recruiting	`NCT03744962` - MSI in Circulatory DNA of Endometrial Cancer
Recruiting	`NCT04711434` - PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients	Phase 3
Completed	`NCT04131062` - Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants	N/A